使用射波刀机器人放射外科系统进行大分割立体定向放疗治疗颈静脉孔神经鞘瘤的长期临床结局
该研究回顾性分析了74例接受大分割立体定向放疗的颈静脉孔神经鞘瘤患者,中位随访103个月,5年无进展生存率为93.2%,42例(56.8%)肿瘤消退,46例原有颅神经病变改善,14例(18.9%)出现延迟性症状恶化。作者认为该疗法安全有效,可作为主要或辅助治疗策略。
要点
- 中位随访103个月,5年无进展生存率93.2%。
- 42例(56.8%)肿瘤消退,27例(36.5%)稳定,5例(6.8%)进展。
- 46例原有颅神经病变改善,14例稳定,14例恶化;14例(18.9%)出现延迟性症状恶化。
核心结论
- 大分割立体定向放疗被证明是颈静脉孔神经鞘瘤安全有效的初始或辅助治疗策略,尽管14例(18.9%)患者出现一定程度延迟性症状恶化。
- 该治疗选择被证明可提供优异的肿瘤控制和颅神经功能改善。
研究设计与样本
- 回顾性分析2009年1月至2020年1月在本中心接受大分割立体定向放疗的74例颈静脉孔神经鞘瘤患者。
- 其中53例为新诊断,19例有显微外科切除史,2例因伽玛刀放疗后肿瘤复发接受射波刀治疗。
- 73例存在治疗前颅神经症状和体征。
- 中位肿瘤体积14.8 cm3(范围0.5-41.2 cm3),70.3%的肿瘤≥10 cm3。
- 放疗剂量方案根据肿瘤大小决定,较大肿瘤使用更多分次;中位边缘剂量为18.2 Gy/2次、21.0 Gy/3次和21.6 Gy/4次。
主要发现
- 中位随访103个月(范围18-158个月)。
- 42例(56.8%)肿瘤消退,27例(36.5%)肿瘤稳定,5例(6.8%)肿瘤进展;MRI显示1例完全缓解。
- 3例因肿瘤进展在中位25个月时接受手术。
- 1例因大分割立体定向放疗后出现与肿瘤进展无关的脑积水而接受脑室腹腔分流术。
- 5年无进展生存率为93.2%。
临床怎么用
- 作者认为大分割立体定向放疗可作为颈静脉孔神经鞘瘤安全有效的初始或辅助治疗策略。
- 作者指出该治疗选择可提供优异的肿瘤控制和颅神经功能改善。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Jugular foramen schwannomas (JFSs) are rarely seen, benign tumors with slow growth. Today, management options for JFSs include observation, surgery, and radiation. However, the optimal treatment strategy remains controversial. Stereotactic radiosurgery serves as a minimally invasive alternative or adjuvant therapeutic regimen of microsurgery. Gamma Knife radiosurgery is suitable for patients with JFS who have small- and medium-sized tumors and normal cranial nerve (CN) function. Hypofractionated stereotactic radiotherapy (HSRT) offers a potential radiobiological advantage and may result in better preservation of normal structures compared to single-fraction stereotactic radiosurgery. The aim of the article was to review the clinical and radiographic outcomes of patients with JFS who were treated using HSRT. METHODS: The authors retrospectively analyzed 74 patients with JFS who received HSRT between January 2009 and January 2020 in the authors' center. Among them, 53 patients were newly diagnosed with JFS, 19 patients had a previous history of microsurgical resection, and the other 2 patients underwent CyberKnife because of tumor recurrence after Gamma Knife radiosurgery. A total of 73 patients had preexisting CN symptoms and signs. The median tumor volume was 14.8 cm3 (range 0.5-41.2 cm3), and most of them (70.3%) were ≥ 10 cm3. The radiation dose regimen was prescribed depending on the tumor size, and more fractions were used in larger tumors. The median margin doses prescribed were 18.2 Gy/2 fractions, 21.0 Gy/3 fractions, and 21.6 Gy/4 fractions. RESULTS: The median follow-up was 103 months (range 18-158 months). After treatment, 42 (56.8%) patients had tumor regression, 27 (36.5%) patients had stable tumors, and 5 (6.8%) experienced tumor progression. Among them, MRI revealed that 1 patient had a complete response. Three patients received surgery at a median of 25 months because of tumor progression. One patient underwent ventriculoperitoneal shunt insertion for hydrocephalus that developed after HSRT independent of tumor progression. The 5-year progression-free survival rate was 93.2%. Preexisting cranial neuropathies improved in 46 patients, remained stable in 14, and worsened in 14. CONCLUSIONS: HSRT proved to be a safe and effective primary or adjuvant treatment strategy for JFSs, although 14 patients (18.9%) experienced some degree of delayed symptomatic deterioration posttreatment. This therapeutic option was demonstrated to provide both excellent tumor control and improvement in CN function.
引用
- Zou W, Guan Y, Zhu H, et al. Long-term clinical outcomes of hypofractionated stereotactic radiotherapy using the CyberKnife robotic radiosurgery system for jugular foramen schwannomas. J Neurosurg. 2023. PMID: 37976497. doi:10.3171/2023.8.JNS231026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。